Navigation Links
MJFF announces over $10 million in funding for clinical and pre-clinical PD research
Date:10/6/2010

The Michael J. Fox Foundation for Parkinson's Research announced awards totaling approximately $10.1 million for five new clinical studies and 14 pre-clinical therapeutic development projects. The funding includes $2.5 million to drive four new clinical trials under the Clinical Intervention Awards, one of the Foundation's Edmond J. Safra Core Programs for PD Research.

Grantees under the 2010 Clinical Intervention Awards are:

  • Charlotte Keywood, Addex Pharmaceuticals: Dr. Keywood will test a candidate drug that has alleviated dyskinesia in pre-clinical models of PD by targeting a specific glutamate receptor known as mGluR5. This phase 2, double-blind/placebo-controlled study could lead to a new class of treatment for the debilitating side effect of long-term dopamine replacement therapy.

  • Benzi Kluger, University of Colorado, Denver: Dr. Kluger will lead an investigation of acupuncture to treat PD-related fatigue and motor symptoms of the disease. This is one of the first placebo-controlled clinical studies of acupuncture in Parkinson's.

Two separate awardees will independently work on novel formulations of levodopa designed to create an easier treatment regimen for patients while also lessening the complications and symptoms of PD that are believed to be exacerbated by extreme fluctuations in blood levels of levodopa:

  • Verne Cowles, Depomed, Inc.: Dr. Cowles will lead a Phase 1 study testing a new formulation of levodopa/carbidopa that may enable less-frequent dosing.

  • Sheila Oren, NeuroDerm, Inc. (Israel): Dr. Oren will test a new skin patch that administers carbidopa continuously, keeping blood levels of the drug stable over time.

For information on the 15 pre-clinical therapeutic development projects receiving awards totaling $2 million, please visit PD Online Research.

In addition to today's announcement, the Foundation recently launched the Parkinson's Progression Markers Initiative, a landmark clinical study seeking biomarkers of Parkinson's disease. The Foundation has committed $8.6 million to PPMI to date.


'/>"/>

Contact: Holly Barkhymer
hbarkhymer@michaeljfox.org
212-509-0995 x242
The Michael J. Fox Foundation for Parkinson's Research
Source:Eurekalert

Related medicine news :

1. ESC announces new initiatives for workplace heart health programs
2. ASTRO announces 2010 Annual Meeting awards
3. CRF announces featured clinical trials to be presented at TCT 2010
4. CRF announces late breaking trials and first report investigations to be presented at TCT 2010
5. ASP announces 2010 T. Franklin Williams Scholars
6. Feng Shui Expert Practitioner and Analyst Angel de Para Announces Classical Feng Shui Practitioner Workshop in New York City.
7. Lifeloc supports workplace breath alcohol testing and announces new robust solution, the EV30T
8. QualEDIx Announces the Launch of the Nation's Only Managed Service Model for HIPAA 5010 and ICD-10 Testing
9. ASTRO announces 2010 Fellows class
10. NOSCAR announces first NOTES transoral and transvaginal gallbladder removals performed as part of US multicenter human trial
11. Bling My Sling LL Announces Website Launch - A fashionable arm sling manufacturer, announce the opening of their new website bling-my-sling.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... MA (PRWEB) , ... December 08, 2016 , ... ... Workers Compensation Research Institute (WCRI) officially opened registration today for its 33rd ... Hotel in Boston, MA . , The theme of the conference is “Persistent ...
(Date:12/8/2016)... ... 08, 2016 , ... CURE Media Group, the nation’s leading digital and print ... Upstage Lung Cancer in efforts to combat lung cancer, announced CURE Media Group President ... “CURE Media Group is honored to team up with Upstage Lung Cancer in order ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... development continuity to its innovative Unified Instance Manager architecture, meeting the needs ... this new version optimizes the unattended auto-dialing system without agents, Presence Robodialer, ...
(Date:12/8/2016)... City, Ga (PRWEB) , ... December 08, 2016 ... ... moving as soon after surgery as possible. With this in mind, SIGVARIS has ... thrombosis (DVT or blood clot) during bed rest and provide the benefits of ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... planning services from offices headquartered in Jefferson County, is announcing the launch of ... in Birmingham. , The number of homeless women and children in Birmingham has ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Pharmacy, Inc. (NYSE: DPLO) has been recognized by the Detroit ... Standard. To learn more about Diplomat,s career opportunities, visit ... ... ... LLC, a research firm specializing in organizational health and workplace improvement. ...
(Date:12/8/2016)... 8, 2016  Eli Lilly and Company (NYSE: ... phase 3 EXPEDITION3 trial at the 9 th ... disclosed, solanezumab did not meet the primary endpoint in ... in people with mild dementia due to Alzheimer,s disease ... solanezumab for the treatment of mild dementia due to ...
(Date:12/8/2016)... Dec 8, 2016 Research and Markets has ... and Trends - Adhesion Type, Application, Usability - Forecast to 2025" ... , ... Electrodes Market is poised to grow at a CAGR of around ... the market is witnessing include advancements in extracellular microelectrode arrays and ...
Breaking Medicine Technology: